Safety and immunogenicity of ETVAX®, an oral inactivated vaccine against enterotoxigenic Escherichia coli diarrhoea: a double-blinded, randomised, placebo-controlled trial among Finnish travellers to Benin, West-Africa.

Kantele Anu, Riekkinen Marianna, Jokiranta T Sakari, H Pakkanen Sari, Pietilä Jukka-Pekka, Patjas Anu, Eriksson Mari, Khawaja Tamim, Klemets Peter, Marttinen Kati, Siikamäki Heli,Lundgren Anna,Holmgren Jan大牛学者, Lissmats Agneta, Carlin Nils,Svennerholm Ann-Mari大牛学者

Journal of travel medicine(2023)

引用 0|浏览3
暂无评分
摘要
This Phase 2b trial is the largest on ETVAX® undertaken among travellers to date. ETVAX® showed an excellent safety profile and proved strongly immunogenic, which encourages further development of this vaccine.
更多
查看译文
关键词
ETVAX®,enterotoxigenic E. coli (ETEC),immunogenicity,safety,travellers’ diarrhoea (TD)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络